Financial
information
Hofseth BioCare aim to serve the financial market with precise and relevant information about the company to ensure that the share price reflects the underlying values and future prospects. In this section you will find the latest news, presentations, reports and other useful information.
Stock Exchange Notices
- 2018-12-10: Hofseth BioCare ASA: NEW STUDY SHOWS CALGO® IS SUPERIOR TO TRADITIONAL CALCIUM SOURCES ON OSTEOBLAST AND CALCIUM DEPOSITION
- 2018-11-02: Hofseth Biocare ASA: HBC Third Quarter 2018 Financial Report
- 2018-09-26: Hofseth Biocare ASA: REGISTRATION OF SHARE CAPITAL INCREASE
- 2018-09-11: Hofseth Biocare ASA: Result of the subsequent offering
- 2018-09-10: Hofseth Biocare ASA: LAST DAY OF SUBSCRIPTION PERIOD
- 2018-09-06: Hofseth Biocare ASA: New study and US provisional patent filed on regulation of oxidative protective genes in human cells with ProGo for treatment of IBD, such as ulcerative colitis and Crohn's
- 2018-08-27: Hofseth Biocare ASA: HBC Second Quarter 2018 Financial Report
- 2018-08-24: Hofseth Biocare ASA: PUBLICATION OF PROSPECTUS - FURTHER INFORMATION ABOUT THE SUBSEQUENT OFFERING
- 2018-08-02: Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
- 2018-07-16: Hofseth Biocare ASA: Completed Extraordinary General meeting and approved private placement and repair issue
Archive
Why Hofseth BioCare?
- New advanced proprietary process technology
- Producing premium products
- Attractive market proposition
- State of the art production facilities
- Attractive partner model for further growth
- Upside potential within pharma segments
- Management with highly relevant experience
